Menu
Search
|

Menu

Close
X

AcelRx Pharmaceuticals Inc ACRX.OQ (NASDAQ Stock Exchange Global Market)

4.18 USD
-- (--)
As of Jun 19
chart
Previous Close 4.18
Open --
Volume --
3m Avg Volume 64,195
Today’s High --
Today’s Low --
52 Week High 5.75
52 Week Low 1.58
Shares Outstanding (mil) 45.38
Market Capitalization (mil) 231.44
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
8
FY16
17
FY15
19
EPS (USD)
FY18
-0.228
FY17
-0.431
FY16
-0.952
FY15
-0.553
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
14.87
5.71
Price to Book (MRQ)
vs sector
--
5.37
Price to Cash Flow (TTM)
vs sector
--
23.33
Total Debt to Equity (MRQ)
vs sector
--
16.44
LT Debt to Equity (MRQ)
vs sector
--
12.17
Return on Investment (TTM)
vs sector
-63.23
14.38
Return on Equity (TTM)
vs sector
--
16.07

EXECUTIVE LEADERSHIP

Adrian Adams
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Richard King
President, Since 2015
Salary: $490,000.00
Bonus: $91,875.00
Vincent Angotti
Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Raffi Asadorian
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
John Saia
General Counsel, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

351 Galveston Dr
REDWOOD CITY   CA   94063-4736

Phone: +1650.2163500

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

SPONSORED STORIES